# OnCo record ember-3 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ember-3/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ember-3", "NCT04975308" ;
  schema:name "EMBER-3"@en ;
  schema:description "An oral SERD that works alone in ESR1-mutant tumours and, combined with abemaciclib, doubles progression-free time in everyone regardless of mutation."@en ;
  schema:url <https://onco.cc/trials/ember-3/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04975308>, <https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-inluriyo-imlunestrant-adults-er-her2-esr1> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2021-10-04" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/>, <https://onco.cc/targets/cdk4-6/> ;
  onco:drugs <https://onco.cc/drugs/imlunestrant/>, <https://onco.cc/drugs/abemaciclib/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:terms <https://onco.cc/terms/esr1-mutation/>, <https://onco.cc/terms/oral-serd/> ;
  onco:people <https://onco.cc/people/komal-jhaveri/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ember-3-n-engl-j-med-2025/> .